Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for niemann-pick disease type C in a retrospective study

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Welford, Richard W D ^a   Garzotti, Marco ^a   Lourenço, Charles Marques ^b   Mengel, Eugen ^c   Marquardt, Thorsten ^d   Reunert, Janine ^d   Amraoui, Yasmina ^c   Kolb, Stefan A ^a   Morand, Olivier ^a   Groenen, Peter ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Center for Pediatrics and Adolescent Medicine   (Germany)

^d Klinik Für Kinder Und Jugendmedizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLSPHINGOSINE; PSYCHOSINE; SPHINGOLIPID; SPHINGOSYLPHOSPHORYLCHOLINE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; EDETIC ACID; HEPARIN; PHOSPHORYLCHOLINE; SPHINGOSINE; SPHINGOSINE PHOSPHORYLCHOLINE; SPHINGOSYL BETA-GLUCOSIDE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INFANT; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NIEMANN PICK DISEASE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; AGED; ANALOGS AND DERIVATIVES; BLOOD; BLOOD SAMPLING; CASE CONTROL STUDY; CHEMISTRY; NIEMANN-PICK DISEASE, TYPE C; PROCEDURES; REPRODUCIBILITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; BLOOD SPECIMEN COLLECTION; CASE-CONTROL STUDIES; EDETIC ACID; FEMALE; HEPARIN; HUMANS; MALE; NIEMANN-PICK DISEASE, TYPE C; PHOSPHORYLCHOLINE; PSYCHOSINE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SPHINGOSINE; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84917705678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114669     Document Type: Article

References (32)

1. Vanier MT (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 5: 16.
2. Mengel E, Klunemann HH, Lourenco CM, Hendriksz CJ, Sedel F, et al. (2013) Niemann-Pick disease type C symptomatology: An expert-based clinical description. Orphanet J Rare Dis 8: 166.
3. Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, et al. (2013) Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis 8: 12.
4. Bauer P, Balding DJ, Klunemann HH, Linden DE, Ory DS, et al. (2013) Genetic screening for Niemann-Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study. Hum Mol Genet 22: 4349-4356.
5. Wijburg FA, Sedel F, Pineda M, Hendriksz CJ, Fahey M, et al. (2012) Development of a suspicion index to aid diagnosis of Niemann-Pick disease type C. Neurology 78: 1560-1567.
6. Iturriaga C, Pineda M, Fernandez-Valero EM, Vanier MT, Coll MJ (2006) Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci 249: 1-6.
7. Yanjanin NM, Velez JI, Gropman A, King K, Bianconi SE, et al. (2010) Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet 153B: 132-140.
8. Stampfer M, Theiss S, Amraoui Y, Jiang X, Keller S, et al. (2013) Niemann-Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators. Orphanet J Rare Dis 8: 35.
9. Jiang X, Sidhu R, Porter FD, Yanjanin NM, Speak AO, et al. (2011) A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J Lipid Res 52: 1435- 1445.
10. Porter FD, Scherrer DE, Lanier MH, Langmade SJ, Molugu V, et al. (2010) Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med 2: 56-81.
11. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105: 2812-2817.
12. Dekker N, van-Dussen L, Hollak CE, Overkleeft H, Scheij S, et al. (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118: e118-e127.
13. Kodama T, Togawa T, Tsukimura T, Kawashima I, Matsuoka K, et al. (2011) Lyso-GM2 ganglioside: A possible biomarker of Tay-Sachs disease and Sandhoff disease. PLoS One 6: e29074.
14. Chuang WL, Pacheco J, Zhang XK, Martin MM, Biski CK, et al. (2013) Determination of psychosine concentration in dried blood spots from newborns that were identified via newborn screening to be at risk for Krabbe disease. Clin Chim Acta 419: 73-76.
15. Chuang WL, Pacheco J, Cooper S, McGovern MM, Cox GF, et al. (2014) Lyso-sphingomyelin is elevated in dried blood spots of Niemann-Pick B patients. Mol Genet Metab 111: 209-211.
16. Fan M, Sidhu R, Fujiwara H, Tortelli B, Zhang J, et al. (2013) Identification of Niemann-Pick C1 (NPC1) disease biomarkers through sphingolipid profiling. J Lipid Res 54: 2800-2814.
17. Vanier MT (1983) Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim Biophys Acta 750: 178-184.
18. Vanier MT (1999) Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem Res 24: 481-489.
19. EMA (2011) Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/2009).
20. FDA (2001) Guidance for Industry: Bioanalytical Method Validation.
21. Houghton R, Horro Pita C, Ward I, Macarthur R (2009) Generic approach to validation of smallmolecule LC-MS/MS biomarker assays. Bioanalysis 1: 1365-1374.
22. Johnson B, Mascher H, Mascher D, Legnini E, Hung CY, et al. (2013) Analysis of lysoglobotriaosylsphingosine in dried blood spots. Ann Lab Med 33: 274-278.
23. Fast DM, Kelley M, Viswanathan CT, O'Shaughnessy J, King SP, et al. (2009) Workshop report and follow-up-AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples-implications of Crystal City recommendations. AAPS J 11: 238-241.
24. Stevenson L, Garofolo F, Desilva B, Dumont I, Martinez S, et al. (2013) 2013 White Paper on recent issues in bioanalysis: 'hybrid' - The best of LBA and LCMS. Bioanalysis 5: 2903-2918.
25. Crocker AC (1961) The cerebral defect in Tay-Sachs disease and Niemann-Pick disease. J Neurochem 7: 69-80.
26. Lin N, Zhang H, Qiu W, Ye J, Han L, et al. (2013) Determination of 7-ketocholesterol in plasma by liquid chromatography mass spectrometry for rapid diagnosis of acid sphingomyelinase deficient Niemann- Pick disease. J Lipid Res 55: 338-343.
27. Slotte JP (2013) Biological functions of sphingomyelins. Prog Lipid Res 52: 424-437.
28. Lloyd-Evans E, Platt FM (2010) Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic 11: 419-428.
29. Rolfs A, Giese AK, Grittner U, Mascher D, Elstein D, et al. (2013) Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-jewish, caucasian cohort of Gaucher disease patients. PLoS One 8: e79732.
30. Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, et al. (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. Mol Genet Metab 106: 330-344.
31. Zhang H, Wang Y, Lin N, Yang R, Qiu W, et al. (2014) Diagnosis of Niemann-Pick disease type C with 7-ketocholesterol screening followed by NPC1/NPC2 gene mutation confirmation in Chinese patients. Orphanet J Rare Dis 9: 82.
32. Van-Karnebeek CD, Mohammadi T, Tsao N, Sinclair G, Sirrs S, et al. (2014) Health economic evaluation of plasma oxysterol screening in the diagnosis of Niemann-Pick Type C disease among intellectually disabled using discrete event simulation. Mol Genet Metab.